Navigation Links
ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
Date:9/8/2008

Preclinical Pharmacokinetic Data to be Presented at the 7th International

Symposium on Uveitis in Germany

ZURICH, Switzerland, Sept. 8 /PRNewswire/ -- ESBATech AG, a leading developer of antibody fragment therapeutics, today announced that the company has successfully completed its Phase I clinical study of the company's lead product candidate, ESBA105, in ophthalmic indications. In April 2008, ESBATech initiated the Phase I study designed to evaluate the safety, tolerability and pharmacokinetic profile of ESBA105, when delivered topically via eye drops in healthy volunteers. This trial was conducted as a single and repeated dose escalation study in Switzerland. ESBA105 is a single-chain antibody fragment directed against TNF-alpha, and it is being developed initially for ophthalmic indications. Several additional clinical studies are in the preparation stages.

Manfred Zierhut, Professor in the Department of Ophthalmology at the University of Tuebingen in Germany, will present preclinical pharmacokinetic data on ESBA105 on Friday, September 12, 2008, at the 7th International Symposium on Uveitis in Constance, Germany. For more information on the symposium and on Prof. Zierhut's abstract, please visit http://www.iusg2008.org/.

Dominik Escher, Ph.D., Chief Executive Officer of ESBATech AG, commented, "The completion of this Phase I study with ESBA105 in ophthalmic indications marks a critical clinical milestone for the company. Recently, ESBATech secured CHF 23M (USD 22M) in an extended Series B venture financing round. This financing will fund further clinical studies with ESBA105 in ophthalmic indications, as well as build broad franchises in ophthalmology, rheumatology and respiratory diseases for ESBA105 and other antibody fragments. We look forward to announcing the results of this Phase I study and future clinical trials."

Peter Lichtlen, M.D., Ph.D., Hea
'/>"/>

SOURCE ESBATech AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ESBATechs Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
2. Immureboost Inc Announces a Change of Name to Fountain Healthy Aging Inc
3. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
4. MedQuist Announces Additions to Board of Directors
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Martek Announces Third Quarter 2008 Financial Results
7. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
8. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
9. American Oriental Bioengineering Announces Participation in September Investor Conferences
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Mindray Medical International Announces Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 Senior supply chain management executives ... addressed the challenges of “Reducing Cost, Lead Time, & ... strategic sourcing. Describing the partnership of the Bio Supply ... Management Institute ( SCMI) of the University of ... at the Kroc Institute of Peace and Justice in ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... Correct the Record and Provide Accurate Information to ... ... 20 VaxGen,Inc. (Pink Sheets: VXGN), (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ), ... biotechnologies announced on,November 12, 2007 that their respective Boards of Directors ...
... ExL Pharma is pleased to announce the,fall ... leading issues that are,impacting the pharmaceutical industry today. ... networking opportunities for Clinical,Marketing, R&D, and Medical Affairs ... technology companies. Listed below are details on ...
... Tools Experience to the Leader in ... Cellular Bioenergetic Profiling, N. ... tools for real-time measurement of cellular,bioenergetics in microplates, announced today ... the company,s Board of,Directors. In this position, Keegan will apply ...
Cached Biology Technology:VaxGen Addresses MPM Claims in Letter to Stockholders 2VaxGen Addresses MPM Claims in Letter to Stockholders 3VaxGen Addresses MPM Claims in Letter to Stockholders 4VaxGen Addresses MPM Claims in Letter to Stockholders 5VaxGen Addresses MPM Claims in Letter to Stockholders 6VaxGen Addresses MPM Claims in Letter to Stockholders 7VaxGen Addresses MPM Claims in Letter to Stockholders 8VaxGen Addresses MPM Claims in Letter to Stockholders 9Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors 2
(Date:7/10/2014)... , July 3, 2014 Research ... addition of the "Global Gesture Recognition & ... - Forecasts to 2020" report to their ... Global Gesture Recognition & Touch-Less Sensing Market ... around for a while, but the companies were ...
(Date:7/10/2014)... New York , July 7, 2014 ... by Transparency Market Research "Electronic Access Control Systems Market ... 2014 - 2019," the global Electronic Access Control systems ... and is expected to grow at a CAGR of ... value of USD 31,187.8 million in 2019. ...
(Date:7/10/2014)... -- Acuity Market Intelligence today released forecasts from "The Global ... global market for National Electronic ID (eID) programs will generate ... time, the number of National eID cards in circulation will ... , with its vast population, will dominate the market ... Europe trails a distant second at ...
Breaking Biology News(10 mins):Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2
... Through an innovative feat of plant biotechnology and vaccine ... University have successfully turned tobacco plants into vaccine production ... vaccine elicits a protective immune response in guinea pigs. ... the future development of a new vaccine for human ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
... Just as baby mammals depend on their mothers' milk, ... themselves by stripping off and eating the fat-rich outer ... team of researchers that includes University of Michigan biologist ... issue (April 13) of the journal Nature. , Hatchlings ...
Cached Biology News:Plant-derived vaccines safeguard against deadly plague 2Plant-derived vaccines safeguard against deadly plague 3Do plants have the potential to vaccinate against HIV? 2African amphibians make extreme parental sacrifice: The skin off their backs 2African amphibians make extreme parental sacrifice: The skin off their backs 3
MpV17 transgene, murine homolog, glomerulosclerosis...
Mouse monoclonal [6C3] to JAB1 ( Abpromise for all tested applications). entrezGeneID: 10987 SwissProtID: O15386...
Recombinant Ovine (Sheep) Prolactin, Ultra Pure...
Human LT beta R/TNFRSF3 Phycoerythrin MAb (Clone 71319)...
Biology Products: